CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Andrew Hirsch to its board of directors, effective immediately. Mr. Hirsch will also serve as chairman of the audit committee of the board. He is currently Chief Financial Officer of Agios Pharmaceuticals.
“Andrew’s deep experience in biotechnology spans strategy, finance, and operations, and I am pleased to welcome him to our board of directors,” said Katrine Bosley, President and Chief Executive Officer, Editas Medicine. “I am confident that we will benefit from Andrew’s leadership, expertise, and business acumen. His contributions will be vital as we continue to build Editas and work towards our goal of making medicines for people suffering from genetically-defined diseases.”
“I am delighted to join the Editas Medicine board of directors,” said Mr. Hirsch. “I look forward to helping guide the Company as it executes its plans to develop innovative genomic medicines in the years ahead.”
Mr. Hirsch has more than 20 years of experience in a range of strategic and operating roles in business, including more than 15 years in the biotech industry. Prior to his current role at Agios, Mr. Hirsch served as president and chief executive officer of BIND Therapeutics. Earlier in his career, Mr. Hirsch held various leadership roles at Avila Therapeutics and Biogen. Mr. Hirsch holds an MBA from the Tuck School at Dartmouth College and a Bachelor of Arts in Economics from the University of Pennsylvania.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.